Bone marrow biopsy does not add value to PET/CT staging of DLBCL

The use of PET/CT imaging accurately assessed bone marrow involvement in most patients with diffuse large B-cell lymphoma, according to retrospective study results.

Thus, the addition of bone marrow biopsy to PET/CT staging does not add relevant diagnostic or prognostic value for most patients, according to the researchers.

Because bone marrow involvement occurs in up to 25% of newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) and is associated with poor outcomes, random iliac crest bone marrow biopsy has been a standard component of routine staging workup. Read more.

Tags: Bone Cancer PET

About NMC  |  Products  |  Quote  |  News  |  Resources  |  Contact  |  Sitemap